Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Hypertension. 2010 Nov 15;57(1):94–102. doi: 10.1161/HYPERTENSIONAHA.110.160242

Figure 4. Adenoviral-mediated delivery of VEGF121 early in pregnancy prevents the hallmark maternal symptoms and rescues fetal demise in BPH/5.

Figure 4

Summary of radiotelemetric measurements of mean arterial pressure (MAP) before, during and after pregnancy in BPH/5 (panel A) and C57 (panel B) mice. Ad-VEGF or Ad-LacZ were injected by tail vein on e7.5; n=6-8 for each strain and treatment. C) Summary of urinary protein levels at mid- and late-gestation in BPH/5 and C57 mice that had undergone virus injections on e7.5; n=6-12 per group at each time-point. D) Summary of incidence of fetal resorptions at e14.5 in C57 and BPH/5 mice that had undergone virus injections on e7.5; n=8-11 per group. E) Term litter sizes in each of the strains and virus treatment groups; n=11-18 litters per group. *p<0.05 vs baseline in matched strain; #p<0.05 vs BPH/5 Ad-LacZ; †p<0.05 vs C57 in matched treatment.